In addition to improving hepatic insulin sensitivity, low myostatin plasma levels reduce the expression of tumor necrosis factor α (TNFα), a factor involved in the progression of NAFLD to NASH through the induction of hepatic inflammation [60,61]. The gene discussed is TNF; the disease is metabolic dysfunction-associated steatohepatitis.